BETTENCOURT, Brian B,GANESH, Shanthi S,GEORGE, Elizabeth E,HUESKEN, Dieter D,MILSTEIN, Stuart S,SOLOMON, Jonathan J,THOMAS, Emily E,TOUDJARSKA, Ivanka I,TULLAI, Jennifer J,WEILER, Jan J,‧貝騰科特,‧甘納什,‧喬治,‧休斯肯,‧密爾斯廷,‧所羅門,‧托馬斯,‧托賈斯卡,TULLA
申请号：
HK16102257.6
公开号：
HK1214301A
申请日:
2016.02.26
申请国别(地区):
HK
年份:
2016
代理人:
摘要：
The present disclosure relates to methods of treating EPAS1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, psoriasis, Kaposi's sarcoma-associated herpesvirus, preemclampsia, inflammation, chronic inflammation, neovascular diseases, and rheumatoid arthritis, using a therapeutically effective amount of a RNAi agent to EPAS1.
